Recently, the International Helicobacter pylori Prevention and Treatment Medical Forum was held in Sydney, Australia. Australia’s top biomedical experts, professors and many financial and media witnesses. With the most cutting-edge, in-depth insights and new trends as the core, the academic forum discussed the urgent global prevention and control issues of Helicobacter pylori (H. pylori) and the latest international scientific research results. At the same time, the conference announced the anti-pylori probiotic combination developed by EZZ Life Sciences, an Australian listed company.
At the forum, industry leaders such as former CEO and COO of Ausbiotech, Glenn Cross, Chairman of EZZ Life Sciences Board of Directors, and Luis Vitetta, Clinical Professor of Medical School, University of Sydney, delivered important speeches. . Glenn Cross has nearly 40 years of experience in the field of Australian and international life sciences, and has a solid understanding and forward-looking concepts for the Australian and global biotechnology industry. In leading EZZ Life Science’s research on Helicobacter pylori, he mentioned: ” Genomics has been widely used in the treatment of cancer and infectious diseases, but EZZ is one of the few life science companies in the world focusing on key areas, of which the treatment of Helicobacter pylori is an important one.” Professor Luis Vitetta, Australian Microbiology, Nutrition, Probiotics, functional foods, mucosal and cellular immunity and other fields have been deeply cultivated for decades. Through the disclosure of laboratory and clinical data on the combination of Helicobacter pylori and EZZ probiotics, the audience has also been exposed to the latest scientific research breakthroughs of Helicobacter pylori and EZZ. have a deeper understanding.
At the same time, the conference forum was hosted by Gemma Acton, the anchor of Australian Channel 7 and the world’s top business and financial commentator. Over the years, he has covered financial giants such as Goldman Sachs, Merrill Lynch, and Pacific Investment Management Corporation, and has a keen sense of the Australian business market and economy. This time, a summit dialogue was held with EZZ on the breakthrough of this major international topic and the market prospects of the entire industry.
Helicobacter pylori (H. pylori) is the only bacteria that can survive for a long time in the strong acid environment of the stomach (others such as E. coli can survive for a short time). The World Gastrointestinal Organization (WGO) conservatively estimates that at least half of the world’s population is infected with Helicobacter pylori. In developing countries, up to 80% of adults are infected with the bacteria before the age of 50. In China, about 700 million people have been infected with Helicobacter pylori. This is a group of carcinogens of gastric adenocarcinoma identified by the International Agency for Research on Cancer. In early January 2022, with the release of the 15th edition of the carcinogen report by the U.S. Department of Health and Human Services, Helicobacter pylori was clearly listed as a carcinogen, which has caused huge global controversy and concern.
The most common transmission routes of Helicobacter pylori are fecal-oral and oral-oral transmission. The most common clinical manifestation is epigastric pain, accompanied by nausea, vomiting, abdominal distension, belching, and loss of appetite. In severe cases, there will be gastrointestinal bleeding, such as hematemesis, melena, gastric perforation, and duodenal perforation.
EZZ Life Sciences released its annual scientific research breakthrough – EZZ Anti-Pylori Probiotic Combination, which is the world’s first day and night combination therapy. Taking 2 EZZ Helicobacter pylori capsules during the day can synergize with 4 billion live yeast Brady and 7 complex enzymes remove Helicobacter pylori from the body and relieve various pain and discomfort caused by pylori. Take 1 capsule of EZZ anti-pyloric probiotics at night, supplement 50 billion Lactobacillus reuteri and other 8 highly active strains.
At present, the combination has obtained the TGA certification of the Australian Government Food and Drug Administration, and the Lactobacillus reuteri in it has been approved by 3 countries. patent. According to the relevant person in charge of EZZ: “This set of combination products will be available in major pharmacies in Australia and New Zealand and will be exported to China first. It aims to solve a major hidden danger on people’s dinner table and relieve the pain of Helicobacter pylori infection. Bringing people a healthy and high-quality life has always been the scientific research concept advocated by EZZ and the foundation of the leading life science industry.” (Photo source: Forum Organizing Committee)